Table 1.
Characteristics of 4260 participants of the Cardiovascular Health Study according to quartiles of serum fatty acid-binding protein 4
| Sex-specific quartiles of FABP4 (ng/mL) |
||||
|---|---|---|---|---|
| Q1 (1045) | Q2 (1045) | Q3 (1045) | Q4 (1044) | |
| Quartile cut-off points | ||||
| Men | <18.398 | 18.398 to <23.09 | 23.09–29.9 | >29.9 |
| Women | <27.49 | 27.49 to <34.95 | 34.95–45.3 | >45.3 |
| Characteristics | ||||
| Age (years) | 74.4 ± 4.7 | 74.5 ± 5.1 | 74.8 ± 5.3 | 75.0 ± 5.4 |
| Body mass index (kg/m2) | 24.1 ± 3.5 | 26.0 ± 3.6 | 27.6 ± 4.1 | 29.6 ± 5.4 |
| Waist circumference (cm) | 90.0 ± 10.8 | 95.5 ± 10.8 | 99.2 ± 12.0 | 104.7 ± 13.9 |
| Systolic blood pressure (mmHg) | 134.4 ± 20.5 | 135.8 ± 21.7 | 137.2 ± 21.4 | 137.3 ± 21.4 |
| Kilocalories of physical activity | 1628 ± 1781 | 1506 ± 1786 | 1491 ± 1782 | 1170 ± 1560 |
| eGFR by cystatin C (mL/min/1.73 m2) | 83.8 ± 16.7 | 77.3 ± 16.0 | 71.7 ± 15.4 | 60.7 ± 17.5 |
| Cystatin C (mg/L) | 0.96 ± 0.17 | 1.03 ± 0.19 | 1.10 ± 0.22 | 1.33 ± 0.49 |
| HDL (mg/dL) | 58.0 ± 15.2 | 54.3 ± 14.3 | 52.0 ± 13.6 | 49.6 ± 12.9 |
| LDL (mg/dL) | 125.3 ± 32.5 | 128.9 ± 33.7 | 130.1 ± 33.3 | 128.2 ± 35.7 |
| Triglyceride (mg/dL) | 114.3 ± 55.1 | 136.4 ± 78.0 | 151.9 ± 83.4 | 173.3 ± 104.6 |
| C-reactive protein (mg/dL) | 4.3 ± 10.2 | 4.4 ± 9.0 | 5.0 ± 6.7 | 7.3 ± 10.8 |
| BNP (pg/mL) | 213.2 ± 289.5 | 234.2 ± 545.7 | 268.8 ± 601.8 | 426.9 ± 1448.5 |
| Heart rate | 64.2 ± 10.7 | 65.2 ± 11.0 | 66.0 ± 10.4 | 67.4 ± 13.4 |
| African-American | 144 (13.8%) | 145 (13.9%) | 186 (17.8%) | 195 (18.7%) |
| Male | 428 (41.0%) | 428 (41.0%) | 428 (41.0%) | 427 (40.9%) |
| Less than High School education | 229 (21.9%) | 255 (24.4%) | 288 (27.6%) | 305 (29.2%) |
| Oestrogens (among women) | 120 (19.4%) | 92 (14.9%) | 75 (12.2%) | 56 (9.1%) |
| Fair/poor self-reported health | 171 (16.4%) | 162 (15.5%) | 197 (18.9%) | 264 (25.3%) |
| Use of hypertension medication | 386 (36.9%) | 444 (42.5%) | 533 (51.0%) | 657 (62.9%) |
| Hypertension | 502 (48.0%) | 556 (53.3%) | 623 (59.7%) | 679 (65.1%) |
| Prevalent diabetes | 94 (9.0%) | 122 (11.7%) | 153 (14.6%) | 230 (22.0%) |
| Prevalent CHD | 166 (15.9%) | 185 (17.7%) | 196 (18.8%) | 240 (23.0%) |
| AF | 17 (1.6%) | 20 (1.9%) | 25 (2.4%) | 37 (3.5%) |
| Alcohol intake | ||||
| None | 508 (48.6%) | 534 (51.1%) | 583 (55.8%) | 626 (60.0%) |
| < 7 drinks/week | 364 (34.8%) | 371 (35.5%) | 342 (32.7%) | 319 (30.6%) |
| 7–14 drinks/week | 91 (8.7%) | 88 (8.4%) | 74 (7.1%) | 50 (4.8%) |
| > 14 drinks/week | 82 (7.8%) | 52 (5.0%) | 46 (4.4%) | 49 (4.7%) |
| Smoking status | ||||
| Never smoked | 468 (44.8%) | 480 (45.9%) | 492 (47.1%) | 465 (44.5%) |
| Former smoker | 444 (42.5%) | 458 (43.8%) | 451 (43.2%) | 487 (46.6%) |
| Current smoker | 133 (12.7%) | 107 (10.2%) | 102 (9.8%) | 92 (8.8%) |
| LVEF (cohort 1) | ||||
| Normal | 878 (95.7%) | 873 (93.7%) | 847 (94.4%) | 818 (92.2%) |
| Borderline | 27 (2.9%) | 46 (4.9%) | 36 (4.0%) | 55 (6.2%) |
| Abnormal | 12 (1.3%) | 13 (1.4%) | 14 (1.6%) | 14 (1.6%) |
Data are means (±SD) or n (%). There were missing data on waist circumference (n = 4), HDL (n = 10), LDL (n = 80), triglycerides (n = 1), BNP (n = 450), hypertension (n = 4), and LVEF for cohort 1 (n = 29).
LVEF is from the clinic visit in 1989–1990 for cohort 1 and not available for cohort 2 in 1992–1993.
CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; FABP4, fatty acid-binding protein 4.